STAT+: FDA advisers endorse Bluebird gene therapy for rare blood disorder
A panel of advisers to the Food and Drug Administration voted unanimously to recommend approval…
Category: STAT+
STAT+: Florida hospital system sues religious sharing ministry over unpaid medical claims
Orlando Health is suing Liberty HealthShare, a Christian health care sharing ministry, alleging Liberty owes…
STAT+: Pharmalittle: FDA panel endorses Bluebird Bio gene therapy for rare disease; GSK touts RSV vaccine trial results
And so, another working week will soon draw to a close. Not a moment too…
STAT+: GSK says RSV vaccine for older adults ‘offers exceptional protection’
GSK said Friday that its RSV vaccine showed “statistically significant and clinically meaningful efficacy” in…
STAT+: With Cerner deal closed, Oracle chair pitches sweeping vision for health records and artificial intelligence
Oracle chairman and chief technology officer Larry Ellison vowed to prioritize the cloud giant’s health…
STAT+: Pharmalittle: FDA decision on Novavax Covid shot could be delayed; new drug prices rose 20% annually in recent years
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: How high? Prices for newly launched medicines rose 20% annually, analysis finds
Talk about inflation Amid ongoing angst over prescription drug costs, a new analysis finds that…
STAT+: BioSpring Partners closes $245 million first fund as private markets tense up
When Michelle Dipp and Jennifer Lum decided to launch a life sciences growth equity fund…
STAT+: Pharmalittle: FDA panel endorses Novavax Covid shot; FTC to probe pharmacy benefit managers
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT+: FTC will investigate pharmacy benefit managers and their role in prescription drug costs
After months of deliberation, the U.S. Federal Trade Commission has voted unanimously to investigate several…
Opinion: STAT+: How the U.S. can mitigate and prevent medical device shortages
Just weeks after the U.S. declared Covid-19 to be a public health emergency in early…
STAT+: Study suggests a new harm from hospital mergers: less price transparency
Health care economists argue hospital mergers can raise costs and lower quality. And now, a…
.jpg)
STAT+: Pharmalittle: FDA panel will scrutinize Novavax shot for Covid-19; J&J and Emergent accuse each other of breach
Top of the morning to you, and a fine one it is. Blue skies and…
STAT+: Former Lilly manager files whistleblower lawsuit over manufacturing failures at production plant
A former Eli Lilly human resources officer sued the drug company after claiming she lost…
STAT+: A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy
CHICAGO — I met Cel-Sci CEO Geert Kersten for the first time on Monday at…
STAT+: ‘All about strengthening health systems’: New coalition pushes to license cancer drugs to low-income countries
Over the past two decades, public health officials and patient advocacy groups have pushed the…
STAT+: The graveyard of health tech pilots: why some experiments flourish and others fizzle
Pilot programs are health tech’s proving ground: they let health systems test-drive new devices and…
STAT+: Pharmalittle: Cancer drug trial yields remission in every patient; Novartis data hacked by extortionists
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Praxis’ novel antidepressant fails make-or-break trial
A novel antidepressant from Praxis Precision Medicines failed to outperform placebo in a pivotal study,…
STAT+: Adicet ‘gamma-delta’ T cell therapy shows complete remissions in early study of lymphoma patients
CHICAGO — Adicet Bio reported Monday that a unique, off-the-shelf therapy made from a special…
STAT+: With new research, health tech companies try to make a case for virtual diabetes care
For all the time and money health tech companies have poured into developing virtual care…
STAT+: Roche’s Tigit troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target
CHICAGO — Roche had previously announced the failure of its closely tracked anti-TIGIT immunotherapy in…
STAT+: Promising results reported for new generation of CAR-T immunotherapy for myeloma
CHICAGO — Three companies presented Phase 1 clinical trial results on new CAR-T therapies for…
STAT+: Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients
CHICAGO — The cancer drug Enhertu cut the rate of death in a group of…
STAT+: In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients
CHICAGO — The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared…
STAT+: The FDA’s Pazdur on accelerated approval, single-arm studies, and his own future
CHICAGO — When cancer drugs granted accelerated approval in the U.S. later turn out not…
.jpg)
STAT+: Strategist Jared Holt on why innovation may not be such a good thing for the biotech sector
Every year, the meeting of the American Society of Clinical Oncology, or ASCO, is one…
STAT+: Pharmalittle: Bristol Myers will pay $4.1 billion for Turning Point; Europe looks to approve a smallpox vaccine for monkeypox
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion to gain drugs targeting rare cancer mutations
Bristol Myers Squibb said Friday that it is acquiring Turning Point Therapeutics, a biotech that…
STAT+: Neumora, ambitious startup focused on neuroscience, considers filing for an IPO
Neumora Therapeutics, the neuroscience company launched last year in a bid to revitalize a field…
STAT+: Francis Collins: Concern about independence of new moonshot science agency ARPA-H are ‘overblown’
WASHINGTON — Francis Collins thinks the debate surrounding the Biden administration’s new high-stakes research agency…
STAT+: Carbon Health, citing concerns about path to profitability, lays off 250 employees
Carbon Health, which runs dozens of brick-and-mortar clinics and a virtual care business, laid off…
STAT+: Pharmalittle: ‘Gloomy’ report issued on WTO Covid-vaccine proposal; biotech ‘swoon’ hits enterprise value at many companies
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Companies can’t make CAR-T cells for cancer treatment quickly enough. Here’s what they’re doing about it
The shortage of manufacturing slots for CAR-T cells, which has left myeloma patients dying on…
STAT+: Justice Department says sweeping lab test fraud in Texas involved dozens of doctors and front companies
A new Justice Department lawsuit describes a sweeping fraud scheme in which dozens of Texas…
STAT+: More and more biotechs are worth less than their checking accounts
Biotech’s 2021 swoon has settled into a 2022 malaise, with the closely watched XBI index…
STAT+: Italian authorities fine drugmaker for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in Italy have fined a drugmaker nearly $3.8 million for years of “excessive”…
STAT+: Pharmalittle: Pfizer to exit consumer-health joint venture with GSK; access to obesity drugs in U.S. remains ‘dismal’
Top of the morning to you, and a fine one it is, despite the cloudy…
STAT+: Doctors in Arizona are trying to rewrite the surprise billing law to boost their own pay
Doctors in Arizona are crafting a state ballot measure that would modify the new federal…
STAT+: Theranos whistleblower Tyler Shultz on lessons learned, venture capital, and shutting down his own business
SAN FRANCISCO — During the worst moments at Theranos, Tyler Shultz ran. To burn off…
STAT+: A ‘dark horse’ emerges in the DNA sequencing race, boasting a $100 genome
Bay Area biotech Ultima Genomics on Tuesday claimed that its technology can sequence a whole…
STAT+: Former AstraZeneca executive charged with insider trading over Daiichi cancer drug deal
A former AstraZeneca communications executive was accused of insider trading in connection with a partnership…
STAT+: Documents show problems at Novartis facility where cancer drug production was halted
Earlier this month, Novartis took the surprising step of voluntarily suspending production of two therapies…
STAT+: Pharmalittle: GSK to pay up to $3.3 billion for Affinivax; Senate bill tries to avoid another Aduhelm controversy
Good morning, everyone, and welcome to another working week. We hope the weekend respite, which…
STAT+: While a law designed to thwart counterfeit medicines lurches into full force, fake pills keep circulating
As far as Shane Jerominski was concerned, the many bottles of a widely used HIV…
STAT+: The World Health Assembly moves to bolster clinical trials, but some say it falls short
In response to the Covid-19 pandemic, the World Health Assembly adopted a resolution designed to…
STAT+: Key Senate committee proposes a council to ensure FDA better coordinates on accelerated approvals
WASHINGTON — The Senate is taking pains to avoid another Aduhelm controversy. In new bipartisan…
STAT+: ViiV will make it easier for generic companies to copy its HIV prevention shot, but it’s not clear when
In response to criticism, ViiV Healthcare has agreed to license its long-acting injectable HIV prevention…
STAT+: Pharmalittle: Will widening access to a Covid pill cause resistance? Monkeypox vaccine maker doesn’t see ‘panic’
And so, another working week will soon draw to a close. This is, as you…
STAT+: With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment
As Mirati Therapeutics waits for the Food and Drug Administration to complete a review of…